Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering ...

SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of ...

The incidence of invasive breast cancer after conservative treatment for ductal carcinoma in situ (DCIS) decreased by more than 50% over the past 30 years, data from a Dutch cancer registry showed.

Adjuvant therapy in patients with ductal carcinoma in situ who undergo partial mastectomy remains controversial, particularly for low-risk patients (60 years or older, estrogen-positive, tumor extent ...

SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS ...

Please provide your email address to receive an email when new articles are posted on . Patients with DCIS who received tamoxifen had a lower 15-year risk for ipsilateral breast cancer recurrence.

With breast cancer now afflicting nearly 1 in 7 women in the United States, it was entirely appropriate for the first annual Oncology World Congress to dedicate a plenary session to discussing ...

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received ...

Taking time to get a second opinion on breast cancer treatment did not significantly alter the time to treatment, which still occurred within the currently recommended timeframe, a retrospective ...

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...